These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 14634709)

  • 21. Commentary on Halpern et al. (2011): strengthening the case against functionally significant serotonergic neurotoxicity in human MDMA (ecstasy) users.
    Lyvers M
    Addiction; 2011 Apr; 106(4):787-8. PubMed ID: 21371152
    [No Abstract]   [Full Text] [Related]  

  • 22. Neurotoxicity of MDMA: Main effects and mechanisms.
    Costa G; Gołembiowska K
    Exp Neurol; 2022 Jan; 347():113894. PubMed ID: 34655576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What's in a Name? Correlates of Ecstasy Users Knowing or Agreeing that Molly is Ecstasy/MDMA.
    Palamar JJ
    J Psychoactive Drugs; 2018; 50(1):88-93. PubMed ID: 28937933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human psychobiology of MDMA or 'Ecstasy': an overview of 25 years of empirical research.
    Parrott AC
    Hum Psychopharmacol; 2013 Jul; 28(4):289-307. PubMed ID: 23881877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MDMA (3,4-Methylenedioxymethamphetamine) or ecstasy: the neuropsychobiological implications of taking it at dances and raves.
    Parrott AC
    Neuropsychobiology; 2004; 50(4):329-35. PubMed ID: 15539865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MDMA and 5-HT neurotoxicity: the empirical evidence for its adverse effects in humans - no need for translation.
    Parrott AC
    Br J Pharmacol; 2012 Jul; 166(5):1518-20; discussion 1521-2. PubMed ID: 22404300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of MDMA (ecstasy), and multiple drugs use on (simulated) driving performance and traffic safety.
    Brookhuis KA; de Waard D; Samyn N
    Psychopharmacology (Berl); 2004 May; 173(3-4):440-5. PubMed ID: 14714102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MDMA, cortisol, and heightened stress in recreational ecstasy users.
    Parrott AC; Montgomery C; Wetherell MA; Downey LA; Stough C; Scholey AB
    Behav Pharmacol; 2014 Sep; 25(5-6):458-72. PubMed ID: 25014666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lost in translation: preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans.
    Green AR; King MV; Shortall SE; Fone KC
    Br J Pharmacol; 2012 Jul; 166(5):1523-36. PubMed ID: 22188379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is there a case for MDMA-assisted psychotherapy in the UK?
    Sessa B
    J Psychopharmacol; 2007 Mar; 21(2):220-4. PubMed ID: 17329304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MDMA, serotonergic neurotoxicity, and the diverse functional deficits of recreational 'Ecstasy' users.
    Parrott AC
    Neurosci Biobehav Rev; 2013 Sep; 37(8):1466-84. PubMed ID: 23660456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study.
    de Sola Llopis S; Miguelez-Pan M; Peña-Casanova J; Poudevida S; Farré M; Pacifici R; Böhm P; Abanades S; Verdejo García A; Langohr K; Zuccaro P; de la Torre R
    J Psychopharmacol; 2008 Jul; 22(5):498-510. PubMed ID: 18208910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is frequent dosing with ecstasy a risky business for dopamine-containing neurons?
    O'Shea E; Colado MI
    Trends Pharmacol Sci; 2003 Jun; 24(6):272-4. PubMed ID: 12823951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A clinical crossroads for MDMA.
    Guillot C
    J Psychoactive Drugs; 2005 Dec; 37(4):445-7. PubMed ID: 16480172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse symptomatology and suicide associated with the use of methylenedioxymethamphetamine (MDMA; "Ecstasy").
    Cohen RS
    Biol Psychiatry; 1996 May; 39(9):819-20. PubMed ID: 8731525
    [No Abstract]   [Full Text] [Related]  

  • 36. More about parkinsonism after taking ecstasy.
    Baggott M; Mendelson J; Jones R
    N Engl J Med; 1999 Oct; 341(18):1400-1. PubMed ID: 10577097
    [No Abstract]   [Full Text] [Related]  

  • 37. Does recreational ecstasy use cause long-term cognitive problems?
    Kelly PA
    West J Med; 2000 Aug; 173(2):129-30. PubMed ID: 10924441
    [No Abstract]   [Full Text] [Related]  

  • 38. Patterns of drug use and the influence of gender on self-reports of memory ability in ecstasy users: a web-based study.
    Rodgers J; Buchanan T; Scholey AB; Heffernan TM; Ling J; Parrott AC
    J Psychopharmacol; 2003 Dec; 17(4):389-96. PubMed ID: 14870950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Parkinsonism after taking ecstasy.
    Mintzer S; Hickenbottom S; Gilman S
    N Engl J Med; 1999 May; 340(18):1443. PubMed ID: 10328712
    [No Abstract]   [Full Text] [Related]  

  • 40. Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a WWW study.
    Scholey AB; Parrott AC; Buchanan T; Heffernan TM; Ling J; Rodgers J
    Addict Behav; 2004 Jun; 29(4):743-52. PubMed ID: 15135556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.